Medicine guide

Hepsera

·

  • Prescription status not stated
  • Antibiotics, antivirals and antifungals taken into the body
Active substance
Adefovir dipivoxil
Made by
Gilead Sciences Ireland UC

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

  • Hepsera is indicated for the treatment of chronic hepatitis B in adults with: compensated liver disease with evidence of active viral replication, persistently elevated serum-alanine-aminotransferase (ALT) levels and histological evidence of active liver inflammation and fibrosis. Initiation of Hepsera treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate (see section 5.1); decompensated liver disease in combination with a second agent without cross-resistance to Hepsera.

From the official label · 2026-09-30 · European Medicines Agency

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

SpainNo exact match for this strength and form

CanadaNo exact match for this strength and form

Details

Made byGilead Sciences Ireland UC
Active substanceAdefovir dipivoxil
Used inAntibiotics, antivirals and antifungals taken into the body
ClassificationJ05AF08 · Antibiotics, antivirals and antifungals taken into the body
Authorised on2003-03-06
Last updated by the regulator2023-03-06
EMA product numberEMEA/H/C/000485

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).